Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

Biogen’s gamble on multiple sclerosis drug opicinumab looks increasingly likely to fail after a mid-stage trial upset – but instead of “big bets” on novel medicines the slightly less risky ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

The first-quarter earnings season for the drug and biotech sector will be in full swing this week, with many large drugmakers ...